Search Results

East Denmark Registry Used to Study 10-Year Changes in Use of TAVR and SAVR

June 13, 2016—A study that evaluated the choice of treatment for severe aortic valve stenosis in Eastern Denmark in the era of transcatheter aortic valve replacement (TAVR) was published by Ole De Backer, MD, et al in the Journal of the American College of Cardiology (JACC): Cardiovascular Interventions (2016;9:1152–1158).

FEops HeartGuide for LAAC Procedures Studied in Published PREDICT-LAA Trial

February 24, 2023—FEops, a Belgium-based developer of the HeartGuide cloud-based procedure planning solution, announced the publication of the PREDICT-LAA study showing that left atrial appendage closure (LAAC) procedures planned by means of HeartGuide resulted in significant improvement of procedural efficiency and outcomes.

Conformal Launches European GLACE Study of Next-Generation CLAAS AcuForm LAAO Device

October 1, 2024— Conformal Medical, Inc. announced the initiation of the GLACE Study.

FEops HeartGuide for Planning LAAO Procedures Evaluated in the PREDICT-LAA Trial

September 17, 2022—FEops, a Belgium-based developer of the HeartGuide cloud-based procedure planning solution, announced that data from the PREDICT-LAA trial demonstrated that left atrial appendage occlusion (LAAO) procedures planned via HeartGuide resulted in significantly improved procedural efficiency and outcomes.

Anteris DurAVR THV Studied in Patients With Small Aortic Annuli

November 17, 2025—Anteris Technologies Global Corporation announced 30-day clinical outcomes in 100 severe aortic stenosis patients with small aortic annuli (SAA; aortic annulus area, 404 ± 37 mm2) treated with the company’s small-size DurAVR transcatheter heart valve (THV).

CardioFlow’s VitaFlow Liberty TAVI/TAVR System Granted CE Mark Under European MDR

June 25, 2024—MicroPort CardioFlow Medtech Corporation (CardioFlow), which is headquartered in Shanghai, China, recently announced that it has received CE Mark certification under the European Union’s Medical Device Regulation (MDR) for the VitaFlow Liberty transcatheter aortic valve and retrievable delivery system.

PREDICT-LAA Trial Enrolls First Patient to Study FEops HeartGuide Computer Simulation Device

January 17, 2020—FEops announced that the first patient has been enrolled in the physician-initiated PREDICT-LAA trial.

FEops Heartguide Platform Receives CE Mark Approval for Planning Structural Heart Interventions

April 1, 2019—FEops announced CE Mark approval for the Heartguide procedural planning environment for structural heart interventions.

FEops HeartGuide Receives FDA Clearance for Planning Structural Heart Interventions

July 13, 2023—Belgium-based FEops recently announced the release of the company’s HeartGuide cloud-based procedure planning solution, which includes an artificial intelligence (AI)–based anatomic analysis of multislice CT images for the preoperative planning of structural heart interventions.

Peijia Medical and inQB8 Medical Report FIH Implantation of MonarQ TTVR System

December 2, 2022—inQB8 Medical Technologies, LLC, in partnership with Peijia Medical Limited, recently announced a successful transcatheter tricuspid valve replacement (TTVR) procedure with the MonarQ transcatheter tricuspid valve (TTV) in a 75-year-old female with severe torrential tricuspid regurgitation.